International Institute of Cancer Immunology, Inc. Patent applications |
Patent application number | Title | Published |
20160114019 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 04-28-2016 |
20160051652 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 02-25-2016 |
20150361147 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 12-17-2015 |
20150292035 | RECEPTOR GENE FOR PEPTIDE CANCER ANTIGEN-SPECIFIC T CELL - The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence. | 10-15-2015 |
20150292034 | RECEPTOR GENE FOR PEPTIDE CANCER ANTIGEN-SPECIFIC T CELL - The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence. | 10-15-2015 |
20150238587 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 08-27-2015 |
20150080321 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 03-19-2015 |
20140315758 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 10-23-2014 |
20140315735 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 10-23-2014 |
20140255941 | RECEPTOR GENE FOR PEPTIDE CANCER ANTIGEN-SPECIFIC T CELL - The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence. | 09-11-2014 |
20140199332 | METHOD OF TREATING CANCER WITH AN HLA-A*3303-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide. | 07-17-2014 |
20140193443 | METHOD OF TREATING CANCER WITH AN HLA-A*3303-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide. | 07-10-2014 |
20140193442 | METHOD OF TREATING CANCER WITH AN HLA-A*3303-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide. | 07-10-2014 |
20140134200 | HLA-A* 1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided. | 05-15-2014 |
20140046036 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 02-13-2014 |
20140023670 | CANCER VACCINE COMPOSITION - A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof. | 01-23-2014 |
20130266958 | METHOD FOR ACTIVATING HELPER T CELL - The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1* 0101 molecule, an HLA-DRB1* 0401 molecule, an HLA-DRB1* 0403 molecule, an HLA-DRB1* 0406 molecule, an HLA-DRB1* 0803 molecule, an HLA-DRB1* 0901 molecule, an HLA-DRB1* 1101 molecule, an HLA-DRB3* 0202 molecule, an HLA-DRB4* 0101 molecule, an HLA-DPB1* 0201 molecule or an HLA-DPB1* 0301 molecule, and the like. | 10-10-2013 |
20130243800 | HLA-DR-BINDING ANTIGEN PEPTIDE DERIVED FROM WT1 - The present invention provides a method of treating or preventing cancer, by administering a peptide consisting of 16-25 contiguous amino acids in the amino acid sequence of human WT1 of SEQ ID NO: 1, which has the amino acid sequence of SEQ ID NO: 24, an expression vector having a polynucleotide encoding said peptide or a cell containing the expression vector to a subject in need thereof. | 09-19-2013 |
20130225502 | COMBINATION THERAPY WITH W T 1 PEPTIDE VACCINE AND TEMOZOLOMIDE - The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide. | 08-29-2013 |
20130196427 | CANCER ANTIGEN PEPTIDES DERIVED FROM WT1 - The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide. | 08-01-2013 |
20110229506 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 09-22-2011 |
20110070251 | CANCER VACCINE COMPOSITION - A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof. | 03-24-2011 |
20100190163 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 07-29-2010 |
20100062013 | CANCER ANTIGEN PEPTIDES DERIVED FROM WT1 - The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide. | 03-11-2010 |
20100062010 | NOVEL PEPTIDE COMPOUND - A novel compound of the formula (1): | 03-11-2010 |
20090325886 | WT1 MODIFIED PEPTIDE - The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide. | 12-31-2009 |
20090281043 | TUMOR ANTIGEN BASED ON PRODUCTS OF THE TUMOR SUPPRESSOR GENE WT1 - A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen. | 11-12-2009 |
20090263409 | CANCER ANTIGEN PEPTIDE FORMULATIONS - Cancer antigen peptides derived from WT 1 which have an in vivo efficacy, particularly a clinical usefulness, and cancer vaccines as dosage forms suitable for said cancer antigen peptides, are provided. | 10-22-2009 |
20090143291 | TUMOR ANTIGEN BASED ON PRODUCTS OF THE TUMOR SUPPRESSOR GENE WT1 - A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen. | 06-04-2009 |
20090099090 | HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES - HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients. | 04-16-2009 |